chinese-drug-maker-seeks-nyse-listing

Chinese drug maker seeks NYSE listing

The company banks on an ageing Chinese population and higher urban wealth to drive growth of its key drug.
Tongjitang Chinese Medicines, which owns one of ChinaÆs most well-known pharmaceutical brands, is on the road trying to drum up interest for an initial public offering. Its plan to raise up to $168 million on the New York Stock Exchange may have become a little harder to achieve following the sharp correction in global equity markets this week.

However, people involved with the offering argue that the companyÆs fast growth rate, its focus on the elderly as its primary patient group its flagship drug is used to treat osteoporosis, and the inclusion two years ago of that drug into ChinaÆs national insurance programme should make this an interesting stock for international investors keen to...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222